Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Author affiliations: National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia (V. Ouk, H.L. Say); Laboratory of the National Institute of Public Health, Phnom Penh (M. Virak); World Health Organization Office of Cambodia, Phnom Penh (S. Deng); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R. Frankson, R. McDonald, E.N. Kersh); World Health Organization, Geneva, Switzerland (T. Wi, I. Maatouk); The University of Sydney, Sydney, New South Wales, Australia (S.J. van Hal); The Prince of Wales Hospital, Randwick, New South Wales, Australia (M.M. Lahra); The University of New South Wales, Sydney (M.M. Lahra)

The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) was established in Cambodia in 2020. The program is led by the National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Cambodia, in partnership with the WHO headquarters, regional and country offices, and WHO Collaborating Centres based in the US Centers for Disease Control and Prevention (Atlanta, GA, USA) and New South Wales Health Pathology (Sydney, NSW, Australia). The WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance in Australia provides technical support for the surveillance, including whole-genome sequencing of isolates. As part of the EGASP protocol, Neisseria gonorrhoeae isolates were collected from men with urethral discharge seen at 6 sentinel clinics in Phnom Penh and 4 sentinel clinics in neighboring provinces. EGASP protocols are set to alert public health authorities of strains approaching resistance. EGASP sets N. gonorrhoeae MIC alerts for ceftriaxone, cefixime, gentamicin, and azithromycin (1) (Table).

The first report from EGASP (2) detailed findings from 76 N. gonorrhoeae isolates collected by EGASP in Cambodia in 2022 and tested at the WHO Collaborating Centre for Sexually Transmitted Infections (STIs) and antimicrobial resistance in Australia. Of those, 29/76 (38%) isolates had alert level MICs for ceftriaxone (MIC >0.125 μg/mL) and cefixime (MIC >0.25 μg/mL) (1) and were also resistant to penicillin and ciprofloxacin. Almost all isolates harbored the mosaic penA-60.001 allele (n = 27) across 9 multilocus sequence types (MLSTs), determined by in silico typing. Those findings suggested that penA-60.001 allele carriage is more extensive than previously reported and indicated that widespread dissemination across the region might have already occurred (2) Furthermore, 3 penA-60.001–containing isolates (3/76; 4%) had an extensively drug resistant (XDR) phenotype (3), all from a single sequence type (ST), ST-16406, and similar to previously reported XDR N. gonorrhoeae isolates with links to the region (3).

We present data from an additional 72 gonococcal isolates collected in 2023 by the Cambodia EGASP team and referred to the WHO Collaborating Centre in Australia for phenotypic and genomic analysis. All 72 isolates underwent antimicrobial susceptibility testing. EGASP alert MICs for ceftriaxone and cefixime were detected in 22/72 (31%), a proportion similar to that reported in 2022 (38%) (2) (Table). In 2023, a total of 9 (12.5%) isolates had the XDR phenotype and the same MLST, ST-16406, a 3-fold increase from 4% of isolates with the same phenotype reported in 2022 (3/76). The percentage of isolates with resistance or elevated MICs to ciprofloxacin and penicillin remained high (82%–97%, Table).

Figure

Figure. Circular midpoint rooted phylogeny of sequences from Neisseria gonorrhoeaeisolates collected by the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2022–2023. Associated metadata, year of isolation, MLST,...

Genomic analysis (2) showed that, of the 54 isolates with ceftriaxone alert MICs in 2022 and 2023, a total of 50 harbored the penA-60.001 allele and 3 harbored the recently described mosaic penA-273.001 allele (4). The remaining isolate harbored a novel allele classified as penA-60.003, which differed from penA-60.001 by a single-nucleotide polymorphism. Compared with 2022, the 2023 penA-60.001 allele was seen across 5 similar MLSTs (ST-1587, ST-7363, ST-8130, ST-11368, and ST-16406) and 3 other MLSTs (ST-7827, ST-14950, novel ST). Critically, across the 2 years of the EGASP study, sequences from only 8 isolates from Cambodia clustered with the widely disseminated FC428 clone (5), confirming both expansion of newly emerging resistant clones and ongoing emerging resistance across new phylogenetic backbones (Figure). Moreover, all N. gonorrhoeae isolates with azithromycin MICs >256 μg/mL were found to possess the 23S rRNA gene mutation (A2509G). All 12 isolates with an XDR phenotype detected during 2022–2023 belonged to a single ST (ST-16406), recently reported in Europe and the United Kingdom (3). Sequence reads are available from the National Center for Biotechnology Information (BioProject no. PRJNA909328).

Our data provide further evidence for sustained transmission of N. gonorrhoeae strains with elevated MICs for ceftriaxone and increased expansion of isolates with elevated MICs to ceftriaxone and azithromycin that genomically cluster with the XDR N. gonorrhoeae phenotype. Furthermore, strains with elevated MICs for ceftriaxone continue to emerge across different phylogenetic backbones separate from the previously described FC428 clone, confirming concerns that biological fitness is not compromised by that allele (5) and consequently poses a substantial threat for gonococcal disease control.

The proportion of concerning isolates detected across the 2 years (2022–2023) of WHO EGASP Cambodia is of considerable concern, given the implications for future empirical therapy. Moreover, 2 recent publications from China report rates of N. gonorrhoeae with ceftriaxone MICs >0.125 μg/mL at or beyond 9%, most associated with the mosaic penA-60.001 allele (7.8), suggesting a far wider regional problem. That gonococcal antimicrobial resistance surveillance across the Asia–Pacific region is largely unmapped (9) reinforces high-level concerns regarding this priority pathogen. There is an urgent need to prioritize surveillance and data reporting to inform local and regional disease prevention and control strategies.

Dr. Ouk is the director of the National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia. His research interests include human immunodeficiency virus and sexually transmitted infections.

Members of the EGASP Cambodia Working Group: Phal Kun Mom (National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia), Vivian Fensham (Integrated Quality Laboratory Services, Villeurbanne , France), Kristen M. Kreisel (Centers for Disease Control and Prevention and WHO Collaborating Centre for Sexually Transmitted Infections Prevention, Atlanta, GA, USA; Martina Escher (WHO Global HIV, Hepatitis and STI Programmes, Geneva, Switzerland), Kiyohiko Izumi, Takeshi Nishijima (WHO Regional Office for the Western Pacific, Manila, the Philippines), Magnus Unemo (WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Örebro, Sweden), Ratan L. Kundu, Sanghamitra Ray, Tiffany R. Hogan (WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, Australia).

Top